ReviewAnnals of medicine and surgery (2012)2025
Gold nanoparticles in cardiovascular medicine: current applications and future directions in nano-cardiology.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gold nanoparticles (GNPs) are poised to revolutionize the diagnosis and treatment of cardiovascular diseases (CVDs). This review uniquely synthesizes current research by focusing on three critical, interlinked advancements that address key translational challenges in nano-cardiology: (1) the precise engineering of size-optimized GNPs (20-50 nm) to enhance hemodynamic stability and targeted tissue penetration, overcoming limitations of broader size ranges; (2) the development of dual-modality imaging probes specifically designed to leverage macrophage-targeted photoacoustic signals for precise and early detection of vulnerable atherosclerotic plaques, a significant unmet diagnostic need; and (3) the innovation of stimuli-responsive drug delivery systems that exploit GNPs' tunable surface chemistry to achieve localized and efficient therapeutic effects, thereby minimizing systemic toxicity and improving drug concentrations at diseased sites. We critically examine how these advancements are transforming early CVD detection (e.g., highly sensitive heart attack diagnostics), targeted therapies (e.g., specific drug delivery for heart failure), and regenerative medicine (e.g., enhanced cardiac tissue repair). Finally, we identify current challenges, such as ensuring rigorous biocompatibility and optimizing blood flow interactions, and propose specific, actionable strategies to accelerate the translation of these promising laboratory discoveries into clinical practice, charting a clear path for the next generation of nano-cardiology solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.